Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.47 |
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 6/20 | 0.39 |
| ▸ | TDO2 | P48775 | 6/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24204600 | 0.81 | NPC1 (0.59) | NPC1RAB9ACASP3SENP7IDO1 | |
| SCHEMBL30389877 | 0.81 | NPC1 (0.59) | NPC1RAB9ACASP3SENP7IDO1 | |
| SCHEMBL24204822 | 0.80 | NPC1 (0.43) | NPC1RAB9ACASP3SENP7IDO1 | |
| SCHEMBL26874132 | 0.78 | CYP2A6 (0.40) | NPC1RAB9ACASP3SENP7IDO1 | |
| SCHEMBL24204669 | 0.78 | NEK2 (0.45) | NPC1RAB9AIDO1TDO2PDGFRB | |
| SCHEMBL30390005 | 0.78 | NEK2 (0.45) | NPC1RAB9AIDO1TDO2PDGFRB | |
| SCHEMBL24204704 | 0.77 | KDM5B (0.42) | NPC1RAB9AIDO1TDO2PDGFRB | |
| SCHEMBL30523281 | 0.77 | KDM5B (0.42) | NPC1RAB9AIDO1TDO2PDGFRB | |
| SCHEMBL31010849 | 0.74 | NPC1 (0.54) | NPC1RAB9ACASP3SENP7IDO1 | |
| SCHEMBL31010865 | 0.73 | NPC1 (0.52) | NPC1RAB9ACASP3SENP7IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-11827605-B2 | Isoquinoline compounds and their use in treating AhR imbalance | Dermavant Sciences GmbH (CH) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827605-B2 | Isoquinoline compounds and their use in treating AhR imbalance | AHR, ARNT, HRH1 | NPC1 767/4885RAB9A 2589/4885CASP3 2651/4885 |
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | AHR, ARNT, HRH1 | NPC1 767/4885RAB9A 2589/4885CASP3 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.